CRNX stock forecast
Our latest prediction for Crinetics Pharmaceuticals, Inc.'s stock price was made on the Feb. 10, 2020 when the stock price was at 21.44$.
In the short term (2weeks), CRNX's stock price should underperform the market by -3.38%. During that period the price should oscillate between -11.75% and +10.10%.
In the medium term (3months), CRNX's stock price should underperform the market by -5.78%. During that period the price should oscillate between -37.84% and +30.86%.Get email alerts
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
At the moment the company generates 2M USD in revenues.
On its last earning announcement, the company reported a loss of -1.43$ per share.
The book value per share is -1.05$
Three months stock forecastFeb. 10, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|